Dag Ilver

Title: Dag Ilver: Innovator in Blood Group Antigen Research

Introduction

Dag Ilver is a notable inventor based in Umea, Sweden. He has made significant contributions to the field of biomedical research, particularly in the area of blood group antigens. With a total of 3 patents to his name, Ilver's work has the potential to impact diagnostics and therapies for gastrointestinal diseases.

Latest Patents

Ilver's latest patents include a novel blood group antigen binding (BAB) adhesin protein that has been isolated and purified. This protein specifically binds to fucosylated blood group antigens, and the protein sequence is disclosed in the application. Additionally, the DNA sequences for two genes, babA and babB, which produce highly similar proteins, are also disclosed. This adhesin and/or DNA is useful for diagnosis and therapy directed against induced infections, such as gastritis and acid peptic disease, offering a new method for active vaccination. Another significant patent involves a Helicobacter pylori adhesin binding group antigen, which has a molecular weight of about 73.5 kDa. The N-terminal sequence for this adhesin shows homologies between different strains, making it valuable for diagnosing and treating gastrointestinal diseases.

Career Highlights

Throughout his career, Dag Ilver has focused on innovative solutions in the biomedical field. His research has led to advancements in understanding blood group antigens and their implications for health. His patents reflect a commitment to developing effective treatments and diagnostic tools.

Collaborations

Ilver has collaborated with notable colleagues, including Thomas Boren and Anna Arnqvist. These partnerships have enhanced his research efforts and contributed to the success of his innovations.

Conclusion

Dag Ilver's work in blood group antigen research exemplifies the impact of innovation in the biomedical field. His patents not only advance scientific understanding but also hold promise for improving health outcomes.